Skip to main content
Glama

GMPSignal Real-Time Intelligence MCP (59 Tools)

clinical_trials_fda_drug_pipeline_tracker

Read-onlyIdempotent

Clinical Trials & FDA Drug Pipeline Tracker: Structured feed of active clinical trials, FDA drug approvals, and biotech pipeline updates.

Tool call template

This tool declares no required parameters. Add optional parameters from the input schema as needed.

{
  "id": 1,
  "jsonrpc": "2.0",
  "method": "tools/call",
  "params": {
    "arguments": {},
    "name": "clinical_trials_fda_drug_pipeline_tracker"
  }
}

Input Schema

NameRequiredDescriptionDefault
maxResultsNoMaximum clinical trial records to return.

Schema Changelog

Changes observed during successful MCP inspections.

  1. Changed1 schema field changed
    • changedInput schema / properties / maxResults / description
      Previous value: -"Maximum number of structured items to extract."New value: +"Maximum clinical trial records to return."
  2. Changed1 schema field changed
    • removedInput schema / additionalProperties
      Removed value: -true
  3. Changed1 schema field changed
    • addedInput schema / additionalProperties
      Added value: +true
  4. First observed

TDQS

C2.6/5.0
Behavior2/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnlyHint=true, destructiveHint=false, idempotentHint=true and openWorldHint=true, so the safety and side-effect profile is fully covered by structured data. The description adds nothing beyond that: no data source, refresh cadence, pagination behavior, or coverage geography is disclosed, leaving the openWorld hint unexplained.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

A single front-loaded sentence with no redundant clauses or filler. There is nothing to cut, though the brevity here reflects underspecification rather than disciplined compression.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness2/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema and a data-feed tool spanning trial records, approvals, and pipeline updates, the description should state at minimum what records look like and whether the result set is bounded or unpaginated. Neither is present, so an agent cannot predict the return payload before calling.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Only one parameter (maxResults) exists and the schema documents it at 100% coverage, so the baseline is 3. The description adds no meaning about the parameter, and notably does not clarify that maxResults is described as limiting only trial records even though the feed also returns approvals and pipeline updates.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose3/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description enumerates the three data categories (active clinical trials, FDA drug approvals, biotech pipeline updates), which does distinguish it from the FDA recalls and warning-letter siblings, but it is written as a title-plus-noun-phrase with no verb describing the operation. An agent learns what data domain it touches but not whether calling it lists, searches, or streams anything.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines2/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

There is no statement of when to prefer this tool over fda_recalls_enforcement or fda_warning_letters_scraper, and no mention of the absence of drug/company/phase filtering arguments. The agent must infer usage purely from the tool name.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

Resources